

Amyloid β Peptide-(1–42) Induces Internalization and Degradation of β_2 Adrenergic Receptors in Prefrontal Cortical Neurons^{*[S]}

Received for publication, March 27, 2011, and in revised form, June 19, 2011. Published, JBC Papers in Press, July 11, 2011, DOI 10.1074/jbc.M111.244335

Dayong Wang^{†1}, Eunice Y. Yuen[§], Yuan Zhou[‡], Zhen Yan[§], and Yang K. Xiang^{†¶1,2}

From the [‡]Department of Molecular and Integrative Physiology and the [¶]Neuroscience Program, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801 and the [§]Department of Physiology and Biophysics, State University of New York, Buffalo, New York 14214-3005

Emerging evidence indicates that amyloid β peptide (A β) initially induces subtle alterations in synaptic function in Alzheimer disease. We have recently shown that A β binds to β_2 adrenergic receptor (β_2 AR) and activates protein kinase A (PKA) signaling for glutamatergic regulation of synaptic activities. Here we show that in the cerebrums of mice expressing human familial mutant presenilin 1 and amyloid precursor protein genes, the levels of β_2 AR are drastically reduced. Moreover, A β induces internalization of transfected human β_2 AR in fibroblasts and endogenous β_2 AR in primary prefrontal cortical neurons. In fibroblasts, A β treatment also induces transportation of β_2 AR into lysosome, and prolonged A β treatment causes β_2 AR degradation. The A β -induced β_2 AR internalization requires the N terminus of the receptor containing the peptide binding sites and phosphorylation of β_2 AR by G protein-coupled receptor kinase, not by PKA. However, the G protein-coupled receptor kinase phosphorylation of β_2 AR and the receptor internalization are much slower than that induced by β AR agonist isoproterenol. The A β -induced β_2 AR internalization is also dependent on adaptor protein arrestin 3 and GTPase dynamin, but not arrestin 2. Functionally, pretreatment of primary prefrontal cortical neurons with A β induces desensitization of β_2 AR, which leads to attenuated response to subsequent stimulation with isoproterenol, including decreased cAMP levels, PKA activities, PKA phosphorylation of serine 845 on α -amino-2,3-dihydro-5-methyl-3-oxo-4-isoxazolepropanoic acid (AMPA) receptor subunit 1 (GluR1), and AMPA receptor-mediated miniature excitatory postsynaptic currents. This study indicates that A β induces β_2 AR internalization and degradation leading to impairment of adrenergic and glutamatergic activities.

Alzheimer disease (AD)³ is a progressive neurodegenerative disorder characterized by extracellular amyloid plaques (1).

* This work was supported, in whole or in part, by the National Institutes of Health HL082846 (to Y. X.). This work was also supported by an Alzheimer Association New Investigator Research grant (to Y. X.).

[S] The on-line version of this article (available at <http://www.jbc.org>) contains supplemental Figs. 1–3.

¹ Recipient of a National Alliance for Research on Schizophrenia and Depression award and an Illinois Department of Public Health award.

² To whom correspondence should be addressed: 407 S. Goodwin Ave., Urbana, IL 61801. Tel.: 217-265-9448; Fax: 217-333-1133; E-mail: kevinxy@illinois.edu.

³ The abbreviations used are: AD, Alzheimer disease; A β , amyloid β peptide; β_2 AR, β_2 adrenergic receptor; MEF, mouse embryonic fibroblast; mEPSC,

Mounting evidence suggests that in the early phase of AD, memory loss is due to synaptic malfunction caused by diffusible amyloid β peptide (A β), before neuronal degeneration (2). In supporting this notion, we have recently shown that A β interacts with β_2 adrenergic receptors (β_2 AR) in the central noradrenergic system to regulate synaptic functions in prefrontal cortical (PFC) neurons (3).

The central noradrenergic system is thought to determine the global orientation of the brain concerning events in the external world and within the viscera (4). It plays a critical role in arousal, which is important in regulating consciousness, attention, and information processing and is crucial for promoting certain behaviors such as mobility, learning, and pursuit of food (5). β ARs, an integral part of central noradrenergic system, belong to G protein-coupled receptors (6). In the brain, β AR is widely distributed in different regions, including the frontal, parietal, piriform, and retrosplenial cortices, medial septal nuclei, olfactory tubercle, midbrain, striatum, hippocampus, and thalamic nuclei (7), regulating working memory and other basic brain functions (3, 8, 9). Recent studies have shown that polymorphism of β_2 AR contributes to sporadic late-onset AD (10, 11). During early AD pathogenesis, the central noradrenergic system undergoes substantial changes in response to the degeneration of its main site, the locus ceruleus (LC) (12), and decreased norepinephrine levels (13); however, the levels of adrenergic receptors are not generally increased due to the compensatory mechanism. In fact, a decrease in β_2 AR levels has been observed in different areas of AD brain (14), and β AR response is also decreased in fibroblasts isolated from AD patients (15).

We have recently shown that A β has a binding capacity to β_2 AR that requires the N terminus of the receptor (3). Acute treatment with A β initiates signaling transduction via β_2 AR as an allosteric partial agonist (3, 16, 17). A β binding does not interfere with the binding of catecholamines to the orthosteric binding sites within the receptor transmembrane helices (3). In recent years studies have shown that β_2 AR ligands have signal-

miniature excitatory postsynaptic current; AKAR2.2, A-kinase activity reporter; LC, locus ceruleus; GRK, G-protein coupled receptor C terminal; PFC, prefrontal cortex; β ARKct, β -adrenergic receptor kinase; ARR, arrestin; CFI, cytosolic fluorescence intensity; MFI, membrane fluorescence intensity; PS1, presenilin 1; APP, amyloid precursor protein; Con, control; Tricine, *N*-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine; ANOVA, analysis of variance; β_1 NT, N terminus of β_1 AR.




FIGURE 1. A β induces β_2 AR degradation in vivo and in vitro. *A*, the endogenous β_2 AR in cerebral tissues from wild type (WT) and presenilin 1/amyloid precursor protein (PS1/APP) double transgenic mice were examined with Western blot and quantified. $n = 6$; **, $p < 0.01$, versus control by unpaired t test. *IP*, immunoprecipitate. *B*, HEK293 cells expressing FLAG-tagged human β_2 AR were stimulated with either A β (10^{-6} M) or isoproterenol (Iso, 10^{-7} M) for 4 h. The remaining biotin-labeled β_2 ARs were isolated and blotted, and the Western blots (WB) were quantified. $n = 6$; **, $p < 0.01$ versus control by one-way ANOVA. *C*, HEK293 cells expressing FLAG- β_2 AR were stimulated with A β (10^{-6} M) or isoproterenol (10^{-7} M) for 40 min, and cells were costained with anti-FLAG and anti-Lamp I antibodies.

ing selectivity via inducing differential conformational changes and activation of specific signaling pathways (18–23). Because of the heterogeneous binding property, it is necessary to analyze the action of A β on β_2 AR trafficking and cell function. In addition, A β is not catabolized as quickly as neurotransmitters at synapses, and the concentrations of the peptide are elevated in AD brains; therefore, persistent effects of A β on β_2 AR functions are of pertinence to AD pathology.

PKA, a signaling component downstream to β_2 AR, promotes the function of AMPA receptors by phosphorylating AMPA receptor subunit 1 (GluR1) (24–26). AMPA receptors are ligand-gated ion channels and are one of major mediators of excitatory neurotransmission. We have shown that acute treatment with A β increases β_2 AR- and PKA-dependent phosphorylation of GluR1 and frequency and amplitude of miniature excitatory postsynaptic currents (mEPSCs) mediated by AMPA

A β induces β_2 AR Internalization




FIGURE 2. **A β induces internalization of β_2 AR in HEK293 cells.** *A*, effects of A β or isoproterenol on β_2 AR internalization are shown. Images show time-course effects of A β (10^{-6} M) and isoproterenol (Iso, 10^{-7} M) on β_2 AR internalization. *B*, levels of internalized β_2 AR after A β or isoproterenol treatment were quantified by biotinylation method. $n = 8$; *, $p < 0.05$; **, $p < 0.01$ versus control by two-way ANOVA followed by the modified Tukey test for multiple comparisons.

receptors (3). Here we hypothesize that a persistent treatment with A β , in contrast to its acute effects, may impair cell function by decreasing β_2 AR agonist-induced phosphorylation of GluR1, which is modulated by a GluR1- β_2 AR complex (3, 26, 27). In this study a persistent treatment with A β indeed induces β_2 AR internalization and degradation leading to decreased mEPSCs mediated by AMPA receptors. Moreover, in AD animals, β_2 AR levels in cerebral tissues are significantly reduced, indicating its implication in brain adrenergic and glutamatergic dysfunction in AD.

EXPERIMENTAL PROCEDURES

Animals—Wild type, β_1 AR, β_2 AR, both β_1 AR and β_2 AR gene-knock-out (KO), and presenilin 1/amyloid precursor protein (PS1/APP) transgenic mice were used (28, 29). PS1/APP-transgenic mice overexpress both the human PS1 gene harboring two familial AD mutations, M146L and L286V, and the APP gene (695) with Swedish (K670N, M671L), Florida (I716V), and London (V717I) familial AD mutations. Wild type and PS1/APP transgenic mice (7 months old) were used for analysis of endogenous β_2 AR levels in the cerebrum. All animal experimental procedures were approved by the University of Illinois Animal Care and Use Committee.

Cell Culture and A β Treatment—Newborn WT, β_1 AR-KO, β_2 AR-KO, and β_1/β_2 AR-KO mice were used to isolate PFC neurons under a stereomicroscope (30). Isolated neurons were plated on poly-D-lysine-coated dishes at a density of 1.0×10^5 – 10^6 cells/ml in DMEM/F-12 (1:1) medium containing 10% FBS, 1% insulin-transferin-sodium selenite supplement, 25 ng/ml

nerve growth factor, 1 mM glutamine, 20 nM water-soluble progesterone, and 100 nM putrescine. The next day medium was changed to Neurobasal-A with B-27 supplement. Cytosine β -D-arabinofuranoside (2.5 μ M, Sigma) was added 3 days after plating. Neurons were cultured for 2–3 weeks before experiments. HEK293 cells, wild type mouse embryonic fibroblasts (MEFs), and MEFs lacking either arrestin 2 (ARR2) or arrestin 3 (ARR3) gene were cultured in DMEM medium containing 10% FBS and antibiotics. A β_{1-42} and amino acid sequence-inverted peptide A β_{42-1} (Biopeptide) were dissolved at 10^{-3} M in dimethyl sulfoxide (DMSO) as previously described (31), which yields primarily monomers, dimers, and trimers with low levels of oligomers. Cells were treated with soluble A β_{1-42} peptide as indicated. Our previous study shows that under these conditions A β_{1-42} dimers are the primary species bound to human FLAG- β_2 AR expressed on the plasma membrane (3).

cDNA Constructs—Human FLAG- β_2 AR and human FLAG- β_1 AR are gifts from Dr. Randy Hall (Emory University, GA). The GRK3A mutant β_2 AR lacking three GRK phosphorylation sites and the PKA4A mutant β_2 AR lacking four PKA phosphorylation sites, GFP-ARR3 and V54D dominant negative GFP-ARR3, HA-dynamin, and K44E dominant negative HA-dynamin, and the C terminus of GRK2 (also named β -adrenergic receptor kinase C-terminal (BARKct)) were constructed as described previously (32–34).

Immunofluorescence Microscopy—FLAG-tagged wild type, GRK3A mutant, or PKA4A mutant β_2 AR was expressed in HEK293 cells or MEFs by transfection or in freshly isolated PFC




FIGURE 3. $A\beta$ induces internalization of β_2AR but not β_1AR or chimeric $\beta_1NT-\beta_2AR$. *A*, shown is distribution of FLAG- β_2AR , FLAG- β_1AR , and FLAG- $\beta_1NT-\beta_2AR$, in which the N terminus of the receptor was replaced by that of β_1AR in HEK293 cells after $A\beta$ (10^{-6} M) or isoproterenol (*Iso*, 10^{-7} M) treatment. *B*, shown are representative diagrams of fluorescence intensity in the selected regions of individual cells expressing FLAG- β_2AR , indicated by the yellow frames in panel *A*; the cell membrane is indicated by arrows. *C*, $A\beta$ -induced internalization of β_2AR , β_1AR , or chimeric $\beta_1NT-\beta_2AR$ was quantified with Fiji image-processing package. $n = 16$; *, $p < 0.05$; **, $p < 0.01$ versus control by one-way ANOVA.

neurons by virus infection at 100 multiplicity of infection. After a 2-day expression, cells were treated with drugs for detection with anti-FLAG M1 (Sigma) or anti- β_2AR antibody (Santa Cruz Biotechnology). Wild type and K44E-mutant dynamin were detected with anti-HA antibody (Covance). Lysosomes were stained by anti-Lamp I antibody (BD Pharmingen). Alexa488- and Alexa594-conjugated secondary antibodies (Invitrogen) were used to reveal the primary antibodies. Wild type and V54D-mutant ARR3 and $\beta ARKct$ were indicated by GFP fluorescence. Images were quantified with ImageJ-based Fiji open source image-processing package. Briefly, images were rotated to enable optimal selection of areas across the cell body. Plot profile analysis was applied to selected regions for measure of fluorescence intensity. Average of cytosolic fluorescence inten-

sity (CFI) of β_2AR was divided by that of membrane fluorescence intensity (MFI) for analysis of β_2AR internalization. The ratio of CFI/MFI after stimulation was normalized against the ratio of CFI/MFI at resting state.

Receptor Degradation Assay—After serum starvation, cell surface proteins were labeled with 300 $\mu\text{g/ml}$ biotin (Pierce) in PBS with calcium and magnesium containing 10 mM glucose (PBS/G) at 4 °C for 30 min. Free biotin was quenched with 100 mM glycine in PBS/G for 30 min followed by washing with ice-cold PBS/G. Cells were treated for 4 h with medicines replenished every 30 min. Cells were lysed in ice-cold lysis buffer (25 mM HEPES, pH 7.5 at 4 °C, 10% glycerol, 45 mM NaCl, 2 mM Na_3VO_4 , 5 mM EDTA, 5 mM EGTA, 50 mM NaF, 1% Triton X-100, 8 mM NaN_3 , and protease and phosphatase inhibitor

A β induces β_2 AR Internalization

mixture) and homogenized using a Sonic Dismembrator 100 (Fisher). Streptavidin was added to 300- μ l samples with equivalent protein concentration to precipitate biotin-labeled proteins. Eluates from beads were resolved by SDS-PAGE for detection of biotin-labeled β_2 AR. γ -Tubulin in supernatants was used as control.

Biotin Receptor Internalization Assay—Biotin labeling and quenching were the same as that of the degradation assay. After stimulation, residual surface biotin was stripped off with 50 mM Mesna in NT buffer (150 mM NaCl, 1 mM EDTA, 0.2% BSA, 20 mM Tris-HCl, pH 8.6) twice. The stripped cells were washed, lysed, and homogenized. Streptavidin was added to the samples to precipitate internalized biotin-labeled proteins. Eluates from beads were subjected to Western blot as mentioned above.

APP Processing Assay—Chinese hamster ovary (CHO) cells stably expressing APP cDNA containing the Val \rightarrow Phe mutation at residue 717 (CHO-7PA2) is a gift from Dr. Dennis J. Selkoe (Harvard Medical School Center for Neurologic Diseases). CHO-7PA2 cells were further transfected with human β_2 AR cDNA in poly-D-lysine-coated dishes. Forty-eight hours after the transfection, the cells were starved for 2 h and treated for 4 h in serum-free media with A β (10^{-6} M) or together with CGP 20712A (10^{-5} M) and ICI 118551 (10^{-5} M), which were replenished every 30 min. The environment in the late endosomes and lysosomes is optimal for γ -secretase (35). For detection of APP processing to A β , lysosomes were prepared using the method described previously (36) with adaptation (37, 38). The lysosomes were lysed in 5 mM HEPES, 10% glycerol, 50 mM CH₃COONH₄, 5 mM EDTA, 5 mM EGTA, 1% Triton X-100, and protease inhibitors, pH 8.0. A β in the lysates were immunoprecipitated (39), and samples eluted from sepharose beads were subjected to 16% Tris-Tricine SDS-PAGE. For detection of APP, samples were subjected to 8% Laemmli SDS-PAGE.

Western Blotting—Proteins transferred to nitrocellulose membranes (Millipore) were blocked with 5% milk in blocking buffer (10 mM Tris-HCl, pH 7.4, 100 mM NaCl, 25 mM NaF, 2 mM Na₃VO₄, 8 mM NaN₃, and 0.1% Tween 20). Membranes were incubated with primary antibodies against A β (Cell Signaling), APP (Sigma), β_2 AR, GRK-specific phospho-355/356 of β_2 AR (Santa Cruz Biotechnology), GluR1, and PKA-specific phospho-Ser-845 of GluR1 (Abcam) at 4°C overnight. After washing, membranes were incubated with secondary antibodies for detection with the Li-Cor system (Li-Cor). The optical density of the bands was analyzed with Fiji image-processing package.

Fluorescence Resonance Energy Transfer (FRET) Recording—PFC neurons were infected with viruses to express protein kinase A activity reporter (AKAR2.2) at 37°C for 24 h, then changed to virus-free medium and cultured for another 2 days. PKA activities were recorded as previously described (28, 40). Briefly, cells were rinsed and maintained in PBS/G for FRET recording. Cells were imaged on a Zeiss Axiovert 200M microscope with a 40 \times /1.3NA oil-immersion objective lens and a cooled CCD camera. Dual emission ratio imaging was acquired with a 420DF20 excitation filter, a 450DRLP dichroic mirror, and two emission filters (475DF40 for cyan and 535DF25 for yellow). The acquisition was set with 200-ms exposure in both channels and 20-s elapses.




FIGURE 4. A β -induced β_2 AR internalization requires GTPase dynamin. A, FLAG- β_2 AR was expressed together with either wild type or K44E dominant negative dynamin in HEK293 cells. Cells were stimulated with A β (10^{-6} M) or isoproterenol (Iso, 10^{-7} M) for 40 min, and the distribution of β_2 AR was examined with immunofluorescence staining. B, the images of A β -induced internalization of β_2 AR in panel A were quantified. $n = 16$; **, $p < 0.01$ versus control by one-way ANOVA.

Images in both channels were subjected to background subtraction, and ratios of yellow-to-cyan color were calculated at different time points. In some experiments PFC neurons were pretreated with A β (10^{-6} M) for 40 min, and neurons were then washed 3 times before administration of isoproterenol (10^{-7} M).

Whole-cell Recording in Cultured PFC Neurons—The AMPA receptor-mediated mEPSCs in rat PFC cultures were recorded as described previously (41). The internal solution consisted of 130 mM cesium methanesulfonate, 10 mM CsCl, 4 mM NaCl, 10 mM HEPES, 1 mM MgCl₂, 5 mM EGTA, 2.2 mM QX-314, 12 mM phosphocreatine, 5 mM MgATP, 0.5 mM Na₂GTP, 0.1 mM leupeptin, pH 7.2–7.3, 265–270 mosm. The external solution consisted of 127 mM NaCl, 5 mM KCl, 2 mM MgCl₂, 2 mM CaCl₂, 12 mM glucose, 10 mM HEPES, 1 μ M tetrodotoxin, 5 μ M bicucull-




FIGURE 5. GRK, not PKA, phosphorylation of β_2AR is required for $A\beta$ -induced receptor internalization. *A*, distribution of PKA and GRK phosphorylation site-mutant β_2AR s (PKA4A β_2AR and GRK3A β_2AR) after stimulation with $A\beta$ (10^{-6} M) or isoproterenol (*Iso*, 10^{-7} M) for 40 min in HEK293 cells is shown. *B*, the images of $A\beta$ -induced internalization of β_2AR in *panel A* were quantified. $n = 16$; **, $p < 0.01$ versus control by one-way ANOVA. *C*, Effect of a membrane-permeable PKA inhibitor, myristoylated-PKI, on $A\beta$ -induced β_2AR internalization. Cells were treated with $A\beta$ (10^{-6} M), isoproterenol (10^{-7} M), and PKI (10^{-5} M) for 40 min, and the distribution of the receptor was examined. *D*, the images of $A\beta$ -induced internalization of β_2AR in *panel C* were quantified. $n = 16$; **, $p < 0.01$ versus control by one-way ANOVA.

ine, pH 7.3–7.4, 300–305 mosM. Recording was conducted with a holding potential of -70 mV in the presence of $25 \mu M$ D-2-amino-5-phosphonovalerate to block NMDA receptor-mediated components of mEPSCs. Neurons were treated with 0.1% DMSO or $A\beta_{1-42}$ (10^{-6} M) for 40 min followed by 3 times washing with 0.1% DMSO-containing media. Synaptic currents were analyzed with Mini Analysis Program (Synaptosoft, Leonia, NJ).

Statistical Analyses—Unpaired *t* tests and one- or two-way ANOVA were used to compare different groups with Prism software as indicated (Graphpad). Statistical comparisons of the amplitude and frequency of synaptic currents (mean \pm S.E.) were made using the Kolmogorov-Smirnov test. A *p* value less than 0.05 is considered significant.

RESULTS

During the early development of AD, the central noradrenergic system undergoes substantial changes in response to the degeneration of its main site, the LC. Recent publications have shown that an acute treatment with $A\beta$ initiates signal trans-

duction via β_2AR as an allosteric partial agonist (3, 16, 17). In this study we sought to understand the impact of a prolonged treatment with $A\beta$ (10^{-6} M) on protein levels and function of β_2AR *in vivo* and *in vitro*. We first examined β_2AR protein levels in the cerebrums of 7-month-old PS1/APP double transgenic mice. The β_2AR levels were significantly lower than those in wild type animals (Fig. 1A). In agreement, human β_2AR expressed in HEK293 cells underwent significant degradation after 4 h of treatment with $A\beta$ (10^{-6} M) (Fig. 1B). Accordingly, a 40-min stimulation of human β_2AR induced colocalization of the receptor with the lysosome marker Lamp 1 (Fig. 1C), supporting that β_2AR internalization and degradation occurs after a prolonged treatment with $A\beta$. We then set out to examine whether $A\beta$ induces β_2AR internalization in HEK293 cells. As we expected, the peptide induced significant receptor internalization after a minimal 10-min stimulation (Fig. 2A). The observation was further confirmed with quantitative measurement of internalized receptors labeled with biotin on the cell surface. Cells expressing human β_2AR were labeled with biotin and then stimulated with $A\beta$ or isoproterenol. Biotin remaining on the

A β induces β_2 AR Internalization




FIGURE 6. A β induces GRK-dependent phosphorylation of β_2 AR for internalization. *A*, shown is the effect of β ARKct, a specific inhibitor of GRK2, on A β (10^{-6} M)-induced β_2 AR internalization. *Iso*, isoproterenol. *B*, A β -induced internalization of β_2 AR in *panel A* was quantified. $n = 16$. *C* and *D*, effects of A β on GRK-dependent phosphorylation of β_2 AR are shown. *C*, HEK293 cells expressing β_2 AR were stimulated with different doses of A β for 40 min. A β -induced GRK-dependent β_2 AR phosphorylation was examined and quantified. *D*, HEK293 cells expressing β_2 AR were stimulated with A β (10^{-6} M) for different times. A β -induced GRK-dependent β_2 AR phosphorylation was examined and quantified. *E*, HEK293 cells expressing β_2 AR were stimulated with A β (10^{-6} M), inverted A β (iA β , 10^{-6} M), or isoproterenol (10^{-7} M). A β -induced GRK-dependent β_2 AR phosphorylation was examined and quantified. $n = 6$. *, $p < 0.05$; **, $p < 0.01$ versus control by one-way ANOVA.

cell surface was stripped, and the internalized and biotin-labeled receptors were precipitated and blotted with anti-FLAG antibody. The A β -induced β_2 AR internalization displayed a time-dependent accumulation over 40 min of stimulation, which was slower and less robust than that induced by isoproterenol (Fig. 2*B*). In comparison to β_2 AR, neither β_1 AR nor the chimeric β_1 NT- β_2 AR, in which the N terminus was replaced by that of β_1 AR, showed internalization upon A β treatment (10^{-6} M) (Fig. 3, *A* and *C*), consistent with the fact that they do not have binding capacity to A β (3). As controls, both β_1 AR and the chimeric β_1 NT- β_2 AR displayed significant internalization upon isoproterenol stimulation (Fig. 3, *A* and *C*). Furthermore, we found that the β AR antagonist timolol (10^{-5} M) blocked β_2 AR internalization induced by either A β (10^{-6} M) or isoproterenol (10^{-7} M) (supplemental Fig. 1).

We then examined mechanisms governing A β -induced β_2 AR trafficking. First, we examined whether β_2 AR internaliza-

tion induced by A β is dependent on dynamin GTPase activity. Overexpression of K44E dominant negative dynamin, but not wild type dynamin, almost completely inhibited β_2 AR internalization in HEK293 cells under either A β (10^{-6} M) or isoproterenol (10^{-7} M) stimulation (Fig. 4, *A* and *B*). This suggests that these two ligands induce receptor internalization via similar endocytosis pathways. PKA and GRK can phosphorylate β_2 AR at different sites, which are engaged in dynamin- and arrestin-dependent G protein-coupled receptor desensitization and trafficking. In order to know which kinase is involved in the A β -induced β_2 AR internalization, PKA and GRK phosphorylation site-mutant β_2 ARs, termed PKA4A β_2 AR and GRK3A β_2 AR respectively, were expressed in HEK293 cells. Immunofluorescence staining showed that mutant β_2 ARs lacking PKA phosphorylation sites, not GRK phosphorylation sites, were internalized upon A β (10^{-6} M) treatment (Fig. 5, *A* and *B*). Inhibition of PKA activity by a specific inhibitor, PKI (10^{-5} M),




FIGURE 7. $A\beta$ -induced β_2 AR internalization requires ARR3. *A*, FLAG- β_2 AR was expressed in wild type, ARR2-KO, or ARR3-KO MEFs. Cells were stimulated with $A\beta$ (10^{-6} M) or isoproterenol (Iso, 10^{-7} M) for 40 min, and the distribution of β_2 AR was examined with immunofluorescence staining. *B*, the images of $A\beta$ -induced internalization of β_2 AR in *panel A* were quantified. $n = 16$. **, $p < 0.01$ versus control by one-way ANOVA. *C*, FLAG- β_2 AR was expressed together with either wild type ARR3 or V54D dominant negative ARR3 in HEK293 cells. Cells were stimulated with $A\beta$ (10^{-6} M) or isoproterenol (10^{-7} M) for 40 min, and the distribution of β_2 AR was examined with immunofluorescence staining. *D*, the images of $A\beta$ -induced internalization of β_2 AR in *panel C* were quantified. $n = 16$. **, $p < 0.01$ versus control by one-way ANOVA.

did not block the $A\beta$ -induced β_2 AR internalization (Fig. 5, *C* and *D*). β ARKct, which inhibits GRK2-mediated phosphorylation of β_2 AR, blocked the $A\beta$ -induced β_2 AR internalization (Fig. 6, *A* and *B*). Consistently, $A\beta$ (10^{-6} M), but not amino sequence-inverted $A\beta$ (*iA* β , 10^{-6} M), induced a dose- and time-dependent increase in GRK-dependent phosphorylation of β_2 AR (Fig. 6, *C–E*). The GRK-mediated phosphorylation of β_2 AR occurred at slower kinetics, consistent with the observed slower internalization rate induced by $A\beta$. Next, ARR2 and ARR3 are non-visual arrestins and are involved in G protein-coupled receptor endocytosis. We found that $A\beta$ (10^{-6} M) and isoproterenol (10^{-7} M) induced β_2 AR internalization in wild type and ARR2-deficient MEF cells but not in ARR3-deficient cells (Fig. 7, *A* and *B*). Moreover, $A\beta$ (10^{-6} M) induced β_2 AR internalization in HEK293 cells expressing wild type ARR3 but

not V54D dominant negative ARR3 (Fig. 7, *C* and *D*). Together, these data indicate that $A\beta$ (10^{-6} M) induces GRK2-, ARR3- and dynamin-dependent internalization, although the peptide effects are slower and less potent than those of isoproterenol (10^{-7} M). Furthermore, we found that $A\beta$ (10^{-6} M) treatment increases the processing of APP to yield $A\beta$ (supplemental Fig. 2), consistent with the recent study showing that agonist-induced β_2 AR endocytosis enhances γ -secretase activity for APP processing in lysosomes (35).

To know whether the $A\beta$ -induced β_2 AR internalization impairs neuronal function, we isolated PFC neurons from neonatal mice. A 40-min treatment with $A\beta$ (10^{-6} M) induced significant internalization of endogenous β_2 AR, not β_1 AR (Fig. 8*A*), which was quantified by the biotinylation method (Fig. 8*B*). $A\beta$ (10^{-6} M)-induced β_2 AR internalization was even more evi-

A β induces β_2 AR Internalization




FIGURE 8. A β induces internalization of endogenous β_2 AR and transfected human β_2 AR, not β_1 AR in PFC neurons. *A*, shown is distribution of endogenous β_2 AR or β_1 AR in wild type PFC neurons and overexpressed FLAG- β_2 AR in β_1/β_2 AR-KO PFC neurons after 40 min of treatment with A β (10^{-6} M) or isoproterenol (Iso, 10^{-7} M). *B*, A β -induced internalization of endogenous β_2 AR in PFC neurons was quantified by cell surface biotinylation. $n = 6$. *, $p < 0.05$ versus control by one-way ANOVA.

dent with human β_2 AR overexpressed in β_1 AR/ β_2 AR double-KO PFC neurons (Fig. 8*A*). Next, we investigated β_2 AR-mediated G protein-dependent signal transduction in PFC neurons. A 40-min pretreatment with A β (10^{-6} M) decreased isoproterenol (10^{-7} M)-induced increase in the second messenger cAMP level in the presence of β_1 AR antagonist CGP 20217A (10^{-5} M) (Fig. 9*A*). We also measured PKA activity induced by isoproterenol (10^{-7} M) in live PFC neurons with a FRET-based PKA biosensor AKAR2.2 (Fig. 9, *B–F* (28, 40)). Isoproterenol (10^{-7} M) itself induced a significant increase in PKA activity in wild type neurons (Fig. 9, *C–F*). However, pretreatment with A β (10^{-6} M) dramatically reduced the increase in PKA activity in response to subsequent isoproterenol stimulation. The remaining activity in wild type cells is in part due to activation of β_1 AR, which does not bind to A β (3). β_1 AR-KO neurons were then used to isolate the β_2 AR-specific effect on PKA activity. As expected, although isoproterenol (10^{-7} M) itself induced a significant increase in PKA activity in β_1 AR-KO neurons, pretreatment with A β (10^{-6} M) completely abolished the increase in PKA activity (Fig. 9, *C–F*). In contrast, A β pretreatment did not affect the isoproterenol (10^{-7} M)-induced increase in PKA activity in β_2 AR-KO neurons (Fig. 9, *D* and *F*).

Moreover, in PFC neurons cultured in the presence of β_1 AR antagonist CGP 20217A, pretreatment with A β (10^{-6} M) also decreased isoproterenol (10^{-7} M)-induced increase in PKA-mediated phosphorylation of AMPA receptor subunit GluR1 (Fig. 9*G*). In addition, GluR1 and β_2 AR form a postsynaptic protein complex in neurons (3, 26, 27), and we found that A β (10^{-6} M) also induced internalization of GluR1 in PFC neurons

(supplemental Fig. 3). We also investigated isoproterenol-induced PKA-dependent mEPSCs mediated by AMPA receptors in PFC neurons after pretreatment with A β (Fig. 9, *H–L*). Isoproterenol (10^{-7} M) itself induced a significant increase in mEPSC amplitude (Fig. 9, *H* and *K*) and a small but not significant increase in mEPSC frequency in PFC neurons (Fig. 9, *I* and *L*). However, a 40-min pretreatment with A β (10^{-6} M) abolished isoproterenol-induced increases in AMPA receptor-mediated mEPSCs (Fig. 9, *H–L*).

DISCUSSION

Emerging evidence indicates that A β may induce subtle cellular dysfunction in synaptic plasticity contributing to early memory loss that precedes neuronal degeneration (42). Previous publications show that A β binds to β_2 AR and acutely activates the receptor-mediated signal transduction in both astrocytes and neurons (3, 16, 17). In this study we find that prolonged pretreatment with A β not only induces β_2 AR internalization and degradation but also decreases intracellular cAMP and PKA response to subsequently administered isoproterenol in primary PFC neurons. Because A β is not catabolized or cleared as quickly as catecholamines, it is conceivable that an elevated level of A β induces persistent β_2 AR internalization and degradation in AD. Accordingly, we found that protein levels of β_2 AR in the cerebrums of PS1/APP double transgenic animals are much lower than those in wild type animals. These data indicate that prolonged elevation of A β levels alters postsynaptic responses to neurotransmitters via decreasing β_2 AR levels on the plasma membrane. On the other hand, under




FIGURE 9. Prolonged treatment with Aβ decreases signal transduction mediated by β₂AR for AMPA receptor phosphorylation and activation in PFC neurons. *A–F*, prolonged treatment with Aβ decreases signal transduction mediated by β₂AR. *A*, PFC neurons with or without 40-min pretreatment with Aβ (10⁻⁶ M) were stimulated with isoproterenol (Iso, 10⁻⁷ M) for 5 min in the presence of β₁AR-specific antagonist CGP 20217A (10⁻⁵ M). The isoproterenol-induced increases in cAMP were measured. *n* = 12. *, *p* < 0.05 versus CGP 20217A control, #, *p* < 0.05 versus isoproterenol alone treated group by unpaired *t* test. *B*, indicated is the procedure for FRET recording to measure PKA activities induced by isoproterenol (10⁻⁷ M) after pretreatment with Aβ (10⁻⁶ M). *C–F*, the changes in isoproterenol-induced FRET ratios (PKA activities) after Aβ treatments are shown. The effect of a 40-min pretreatment with Aβ (10⁻⁶ M) on the intracellular PKA FRET ratio in response to isoproterenol (10⁻⁷ M) stimulation in β₁AR-KO PFC neurons (*C*), β₂AR-KO PFC neurons (*D*), or wild type PFC neurons (*E*) is shown. *F*, shown is a bar graph for peak PKA FRET responses in panels *C*, *D*, and *E*. *n* = 7–9. **, *p* < 0.01, versus isoproterenol alone treated group by unpaired *t* test. *G–L*, prolonged treatment with Aβ decreases PKA-dependent GluR1 phosphorylation and AMPA receptor-mediated mEPSCs in response to isoproterenol stimulation in PFC neurons. *G*, PFC neurons were treated with Aβ (10⁻⁶ M) for 40 min as indicated, and cells were then treated with isoproterenol (10⁻⁷ M) for 5 min in the presence of β₁AR antagonist CGP 20217A (10⁻⁵ M) before detection of PKA phosphorylation of GluR1. *n* = 8–14, *, *p* < 0.05; **, *p* < 0.01 versus control; ##, *p* < 0.01 versus a isoproterenol alone-treated group by one-way ANOVA. *GR1*, AMPA receptor subunit GluR1. *H* and *I*, upon a 40-min pretreatment with Aβ (10⁻⁶ M), PFC neurons were treated with isoproterenol (10⁻⁷ M). The time course of amplitude (*H*) and frequency (*I*) of AMPA receptor-mediated mEPSCs was measured. *J*, traces of mEPSCs induced by isoproterenol (10⁻⁷ M) with or without 40 min of pretreatment with Aβ (10⁻⁶ M) is shown. *K* and *L*, the amplitude and frequency of AMPA receptor-mediated mEPSCs in response to isoproterenol (10⁻⁷ M) stimulation in panels *H* and *I* were plotted. *n* = 6. **, *p* < 0.01 versus control by Kolmogorov-Smirnov test for comparisons of the amplitude and frequency of synaptic currents.

chronic Aβ stimulation, persistent cAMP signaling leads to elevated PKA-dependent phosphorylation of its substrates such as GluR1 (3). The elevated basal phosphorylation of GluR1 would likely contribute to the hyperactivities of neurons for imbalanced neuronal network and functions (43), and it would also impair the response to further noradrenergic stimulation under physiological condition.

Consistently, a 40-min pretreatment with Aβ significantly decreases PKA-dependent phosphorylation of GluR1 at Ser-845 in response to subsequently administered isoproterenol

and, as expected, decreases AMPA receptor-mediated mEPSCs in PFC neurons (Fig. 9). This is in contrast to the stimulatory effect on AMPA receptor activity by acute Aβ treatment (3, 24–26). In addition, GluR1, which exists with β₂AR in a post-synaptic protein complex, is also internalized after prolonged Aβ stimulation, consistent with previous observations showing the removal of AMPA receptor from synapse (44). Therefore, this study suggests that a prolonged presence of Aβ in AD brain has dual effects on β-adrenergic and glutamatergic neurotransmission at synapses. First, the Aβ-induced β₂AR signal leads to

A β induces β_2 AR Internalization

elevated basal phosphorylation of AMPA receptor (3) and contributes to hyperactivities of neurons in AD animal models (43). Second, the chronic stimulation also leads to internalization of both receptors and degradation of β_2 AR and impairs β -adrenergic and glutamatergic neurotransmission at synapses. This study also shows that the β AR antagonist, timolol, blocks β_2 AR internalization. Therefore, β AR antagonism may be beneficial in AD patients, as indicated in clinical studies (45).

In the early phase of AD, the central noradrenergic system undergoes substantial changes in response to the degeneration of its main site, the LC, as well as alteration of adrenergic receptor expression in different brain regions including cortical and limbic projection areas (14). LC degeneration results in decreased noradrenaline levels in certain brain regions of AD patients (13). The reduction of LC neurons correlates with A β plaques, neurofibrillary tangles, and the severity of dementia (46). However, norepinephrine levels in cerebrospinal fluids of AD patients are not generally reduced and in some cases are even increased (47, 48). This is probably due to a compensatory sprouting by surviving LC neurons (49). A chronic activation of β_2 AR on neurons in brain areas, including the LC, may contribute to neuronal degeneration due to its regulation on activities of L-type calcium channels and AMPA receptors (3, 26, 27). This paper, on the other hand, suggests a mechanism that A β impairs synaptic function in brain areas receiving noradrenergic projection via decreasing the levels of the receptors on the cell surface. This may also lead to the compensatory increase in presynaptic activities and catecholamine release of the surviving neurons in the LC. In addition, the reduction of adrenergic response in microglia may decrease norepinephrine-mediated anti-inflammatory protection, exacerbate inflammatory events, and reduce A β clearance, thereby exacerbating the situation in AD pathology (50, 51).

A β -induced β_2 AR internalization is both dose- and time-dependent but with a slower kinetics compared with isoproterenol. Although A β induces both GRK- and PKA-dependent phosphorylation of β_2 AR (3), A β -induced internalization is only dependent on GRK2-mediated phosphorylation (52, 53). The slow internalization induced by A β is consistent with the slow phosphorylation of β_2 AR by GRK, which accumulates over 40 min of stimulation. In contrast, isoproterenol induces rapid GRK phosphorylation of β_2 AR, which peaks at 1–2 min of stimulation followed by a gradual decrease (33, 34, 54). Moreover, A β -induced PKA-dependent phosphorylation of β_2 AR is faster compared with GRK phosphorylation, indicating biased signaling transduction associated with conformational changes of β_2 AR (18–23). The structural mechanisms behind these differences remain to be addressed in future. In this study A β -induced β_2 AR internalization is dependent on the non-visual arrestin 3, but not arrestin 2, which also requires dynamin GTPase activity. Together, under A β stimulation, β_2 ARs undergo endocytosis via arrestin-associated and clathrin-coated vesicles (53, 55). In addition, in agreement with the publication that the agonist-induced and clathrin-mediated endocytosis of β_2 AR enhances γ -secretase activity (35), we found that A β -induced β_2 AR internalization also increases the processing of APP to yield A β , which is of significance to AD pathology.

Together, this study reveals a noradrenergic mechanism for decreased synaptic signal transduction in AD, supporting the emerging concept that AD initially centers on soluble A β -induced subtle alterations in synaptic functions. Besides, β_2 AR and its signaling, as an integral part of the central noradrenergic system, is involved in multiple cell functions, including cell differentiation, proliferation, ion channel function, and immunoreactivity of cells in the brain (27, 56–58). Moreover, β_2 AR and AMPA receptor are critical in normal brain functions. Thus, β_2 AR internalization and degradation induced by A β could be generally implicated in various diseases with high levels of A β including AD, Down syndrome, and Parkinson disease (59, 60).

Acknowledgments—We thank Dr. Dennis J. Selkoe at the Harvard Medical School Center for Neurologic Diseases for the CHO-7PA2 cell line. We also thank Mingwei Ding, Xiaoguang Gao, Ruijie Liu, and Vania De Arcangelis for technical assistance.

REFERENCES

1. LaFerla, F. M., and Oddo, S. (2005) *Trends Mol. Med.* **11**, 170–176
2. Selkoe, D. J. (2002) *Science* **298**, 789–791
3. Wang, D., Govindaiah, G., Liu, R., De Arcangelis, V., Cox, C. L., and Xiang, Y. K. (2010) *FASEB J.* **24**, 3511–3521
4. Sara, S. J. (2009) *Nat. Rev. Neurosci.* **10**, 211–223
5. Csikszentmihalyi, M. (1997) *Finding Flow: The Psychology of Engagement with Everyday Life*, pp. 1–34, BasicBooks, New York
6. Ramos, B. P., and Arnsten, A. F. (2007) *Pharmacol. Ther.* **113**, 523–536
7. Asanuma, M., Ogawa, N., Mizukawa, K., Haba, K., Hirata, H., and Mori, A. (1991) *Neurochem. Res.* **16**, 1253–1256
8. Ramos, B. P., Colgan, L. A., Nou, E., and Arnsten, A. F. (2008) *Neurobiol. Aging* **29**, 1060–1069
9. Satler, C., Garrido, L. M., Sarmiento, E. P., Leme, S., Conde, C., and Tomaz, C. (2007) *Acta Neurol. Scand.* **116**, 355–360
10. Yu, J. T., Tan, L., Ou, J. R., Zhu, J. X., Liu, K., Song, J. H., and Sun, Y. P. (2008) *Brain Res.* **1210**, 216–222
11. Rosenberg, P. B., Mielke, M. M., Tschanz, J., Cook, L., Corcoran, C., Hayden, K. M., Norton, M., Rabins, P. V., Green, R. C., Welsh-Bohmer, K. A., Breitner, J. C., Munger, R., and Lyketsos, C. G. (2008) *Am. J. Geriatr. Psychiatry* **16**, 883–892
12. German, D. C., Manaye, K. F., White, C. L., 3rd, Woodward, D. J., McIntire, D. D., Smith, W. K., Kalaria, R. N., and Mann, D. M. (1992) *Ann. Neurol.* **32**, 667–676
13. Matthews, K. L., Chen, C. P., Esiri, M. M., Keene, J., Minger, S. L., and Francis, P. T. (2002) *Biol. Psychiatry* **51**, 407–416
14. Westbroek, W., Lambert, J., Bahadoran, P., Busca, R., Herteleer, M. C., Smit, N., Mommaas, M., Ballotti, R., and Naeyaert, J. M. (2003) *J. Invest. Dermatol.* **120**, 465–475
15. Huang, H. M., and Gibson, G. E. (1993) *J. Biol. Chem.* **268**, 14616–14621
16. Igbavboa, U., Johnson-Anuna, L. N., Rossello, X., Butterick, T. A., Sun, G. Y., and Wood, W. G. (2006) *Neuroscience* **142**, 655–660
17. Echeverria, V., Ducatenzeiler, A., Chen, C. H., and Cuello, A. C. (2005) *Neuroscience* **135**, 1193–1202
18. Reiner, S., Ambrosio, M., Hoffmann, C., and Lohse, M. J. (2010) *J. Biol. Chem.* **285**, 36188–36198
19. Millar, R. P., and Newton, C. L. (2010) *Mol. Endocrinol.* **24**, 261–274
20. Violin, J. D., DiPilato, L. M., Yildirim, N., Elston, T. C., Zhang, J., and Lefkowitz, R. J. (2008) *J. Biol. Chem.* **283**, 2949–2961
21. Wisler, J. W., DeWire, S. M., Whalen, E. J., Violin, J. D., Drake, M. T., Ahn, S., Shenoy, S. K., and Lefkowitz, R. J. (2007) *Proc. Natl. Acad. Sci. U.S.A.* **104**, 16657–16662
22. Drake, M. T., Violin, J. D., Whalen, E. J., Wisler, J. W., Shenoy, S. K., and Lefkowitz, R. J. (2008) *J. Biol. Chem.* **283**, 5669–5676
23. Rajagopal, S., Rajagopal, K., and Lefkowitz, R. J. (2010) *Nat. Rev. Drug Discov.* **9**, 373–386

24. Banke, T. G., Bowie, D., Lee, H., Huganir, R. L., Schousboe, A., and Traynelis, S. F. (2000) *J. Neurosci.* **20**, 89–102
25. Hu, H., Real, E., Takamiya, K., Kang, M. G., Ledoux, J., Huganir, R. L., and Malinow, R. (2007) *Cell* **131**, 160–173
26. Joiner, M. L., Lisé, M. F., Yuen, E. Y., Kam, A. Y., Zhang, M., Hall, D. D., Malik, Z. A., Qian, H., Chen, Y., Ulrich, J. D., Burette, A. C., Weinberg, R. J., Law, P. Y., El-Husseini, A., Yan, Z., and Hell, J. W. (2010) *EMBO J.* **29**, 482–495
27. Davare, M. A., Avdonin, V., Hall, D. D., Peden, E. M., Burette, A., Weinberg, R. J., Horne, M. C., Hoshi, T., and Hell, J. W. (2001) *Science* **293**, 98–101
28. Soto, D., De Arcangelis, V., Zhang, J., and Xiang, Y. (2009) *Circ. Res.* **104**, 770–779
29. Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., Berry, R., and Vassar, R. (2006) *J. Neurosci.* **26**, 10129–10140
30. Chen, C. J., and Liao, S. L. (2003) *J. Neurochem.* **85**, 443–453
31. Tong, L., Thornton, P. L., Balazs, R., and Cotman, C. W. (2001) *J. Biol. Chem.* **276**, 17301–17306
32. Cervantes, D., Crosby, C., and Xiang, Y. (2010) *Circulation Res.* **106**, 79–88
33. Liu, R., Ramani, B., Soto, D., De Arcangelis, V., and Xiang, Y. (2009) *J. Biol. Chem.* **284**, 32279–32287
34. Wang, Y., De Arcangelis, V., Gao, X., Ramani, B., Jung, Y. S., and Xiang, Y. (2008) *J. Biol. Chem.* **283**, 1799–1807
35. Ni, Y., Zhao, X., Bao, G., Zou, L., Teng, L., Wang, Z., Song, M., Xiong, J., Bai, Y., and Pei, G. (2006) *Nat. Med.* **12**, 1390–1396
36. Docherty, K., Brenchley, G. V., and Hales, C. N. (1979) *Biochem. J.* **178**, 361–366
37. Bahadoran, P., Busca, R., Chiaverini, C., Westbroek, W., Lambert, J., Bille, K., Valony, G., Fukuda, M., Naeyaert, J. M., Ortonne, J. P., and Ballotti, R. (2003) *J. Biol. Chem.* **278**, 11386–11392
38. Jadot, M., Dubois, F., Wattiaux-De Coninck, S., and Wattiaux, R. (1997) *Eur. J. Biochem.* **249**, 862–869
39. Klyubin, I., Betts, V., Welzel, A. T., Blennow, K., Zetterberg, H., Wallin, A., Lemere, C. A., Cullen, W. K., Peng, Y., Wisniewski, T., Selkoe, D. J., Anwyl, R., Walsh, D. M., and Rowan, M. J. (2008) *J. Neurosci.* **28**, 4231–4237
40. Zhang, J., Hupfeld, C. J., Taylor, S. S., Olefsky, J. M., and Tsien, R. Y. (2005) *Nature* **437**, 569–573
41. Yuen, E. Y., Liu, W., Kafri, T., van Praag, H., and Yan, Z. (2010) *J. Physiol.* **588**, 2361–2371
42. Small, D. H., Mok, S. S., and Bornstein, J. C. (2001) *Nat. Rev. Neurosci.* **2**, 595–598
43. Busche, M. A., Eichhoff, G., Adelsberger, H., Abramowski, D., Wiederhold, K. H., Haass, C., Staufenbiel, M., Konnerth, A., and Garaschuk, O. (2008) *Science* **321**, 1686–1689
44. Hsieh, H., Boehm, J., Sato, C., Iwatsubo, T., Tomita, T., Sisodia, S., and Malinow, R. (2006) *Neuron* **52**, 831–843
45. Khachaturian, A. S., Zandi, P. P., Lyketsos, C. G., Hayden, K. M., Skoog, I., Norton, M. C., Tschanz, J. T., Mayer, L. S., Welsh-Bohmer, K. A., and Breitner, J. C. (2006) *Arch. Neurol.* **63**, 686–692
46. Bondareff, W., Mountjoy, C. Q., Roth, M., Rossor, M. N., Iversen, L. L., Reynolds, G. P., and Hauser, D. L. (1987) *Alzheimer Dis. Assoc. Disord.* **1**, 256–262
47. Friedman, J. I., Adler, D. N., and Davis, K. L. (1999) *Biol. Psychiatry* **46**, 1243–1252
48. Raskind, M. A., Peskind, E. R., Holmes, C., and Goldstein, D. S. (1999) *Biol. Psychiatry* **46**, 756–765
49. Szot, P., White, S. S., Greenup, J. L., Leverenz, J. B., Peskind, E. R., and Raskind, M. A. (2006) *J. Neurosci.* **26**, 467–478
50. Heneka, M. T., Nadrigny, F., Regen, T., Martinez-Hernandez, A., Dumitrescu-Ozimek, L., Terwel, D., Jandanhazi-Kurutz, D., Walter, J., Kirchhoff, F., Hanisch, U. K., and Kummer, M. P. (2010) *Proc. Natl. Acad. Sci. U.S.A.* **107**, 6058–6063
51. Heneka, M. T., Ramanathan, M., Jacobs, A. H., Dumitrescu-Ozimek, L., Bilkei-Gorzo, A., Debeir, T., Sastre, M., Galldik, N., Zimmer, A., Hoehn, M., Heiss, W. D., Klockgether, T., and Staufenbiel, M. (2006) *J. Neurosci.* **26**, 1343–1354
52. Gurevich, V. V., and Gurevich, E. V. (2004) *Trends Pharmacol. Sci.* **25**, 105–111
53. Gurevich, V. V., and Gurevich, E. V. (2006) *Pharmacol. Ther.* **110**, 465–502
54. Tran, T. M., Jorgensen, R., and Clark, R. B. (2007) *Biochemistry* **46**, 14438–14449
55. Henley, J. R., Cao, H., and McNiven, M. A. (1999) *FASEB J.* **13**, S243–S247
56. Hichami, A., Boichot, E., Germain, N., Berdyshev, E., Coqueret, O., and Lagente, V. (1996) *Mediators Inflamm.* **5**, 425–428
57. Feinstein, D. L. (1998) *J. Neurochem.* **70**, 1484–1496
58. Hu, X. X., Goldmuntz, E. A., and Brosnan, C. F. (1991) *J. Neuroimmunol.* **31**, 35–42
59. Englund, H., Annerén, G., Gustafsson, J., Wester, U., Wiltfang, J., Lannfelt, L., Blennow, K., and Höglund, K. (2007) *Dement. Geriatr. Cogn. Disord.* **24**, 369–374
60. Gallardo, G., Schlüter, O. M., and Südhof, T. C. (2008) *Nat Neurosci* **11**, 301–308